JP7480131B2 - （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置 - Google Patents

（ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置 Download PDF

Info

Publication number
JP7480131B2
JP7480131B2 JP2021518473A JP2021518473A JP7480131B2 JP 7480131 B2 JP7480131 B2 JP 7480131B2 JP 2021518473 A JP2021518473 A JP 2021518473A JP 2021518473 A JP2021518473 A JP 2021518473A JP 7480131 B2 JP7480131 B2 JP 7480131B2
Authority
JP
Japan
Prior art keywords
hours
composition
pharmaceutical composition
cav3
type calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021518473A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020072773A5 (enExample
JP2022504182A (ja
Inventor
エス． リー，マーガレット
パパペトロプロス，スピリドン
エス． ヒギン，ミシェル
ドゥヴリ，ムラリクリシュナ
エヌ． レーレンダー，ブルース
ニューボールド，エヴァン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cavion LLC
Original Assignee
Cavion LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cavion LLC filed Critical Cavion LLC
Publication of JP2022504182A publication Critical patent/JP2022504182A/ja
Publication of JPWO2020072773A5 publication Critical patent/JPWO2020072773A5/ja
Priority to JP2024070307A priority Critical patent/JP2024102139A/ja
Application granted granted Critical
Publication of JP7480131B2 publication Critical patent/JP7480131B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021518473A 2018-10-03 2019-10-03 （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置 Active JP7480131B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024070307A JP2024102139A (ja) 2018-10-03 2024-04-24 （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862740755P 2018-10-03 2018-10-03
US62/740,755 2018-10-03
US201862780049P 2018-12-14 2018-12-14
US62/780,049 2018-12-14
PCT/US2019/054498 WO2020072773A1 (en) 2018-10-03 2019-10-03 Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024070307A Division JP2024102139A (ja) 2018-10-03 2024-04-24 （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置

Publications (3)

Publication Number Publication Date
JP2022504182A JP2022504182A (ja) 2022-01-13
JPWO2020072773A5 JPWO2020072773A5 (enExample) 2022-10-12
JP7480131B2 true JP7480131B2 (ja) 2024-05-09

Family

ID=70055875

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021518473A Active JP7480131B2 (ja) 2018-10-03 2019-10-03 （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置
JP2024070307A Pending JP2024102139A (ja) 2018-10-03 2024-04-24 （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024070307A Pending JP2024102139A (ja) 2018-10-03 2024-04-24 （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置

Country Status (12)

Country Link
US (3) US12383539B2 (enExample)
EP (1) EP3860571A4 (enExample)
JP (2) JP7480131B2 (enExample)
KR (1) KR20210087459A (enExample)
CN (1) CN113164393A (enExample)
AU (2) AU2019355021B2 (enExample)
BR (1) BR112021006398A2 (enExample)
CA (1) CA3115235A1 (enExample)
IL (2) IL282006B2 (enExample)
MX (2) MX2021003706A (enExample)
TW (1) TWI879741B (enExample)
WO (1) WO2020072773A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024102139A (ja) * 2018-10-03 2024-07-30 カビオン・インコーポレイテッド （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3364993T3 (da) 2015-10-22 2023-01-09 Cavion Inc Fremgangsmåder til behandling af angelman syndrom
MX2019012818A (es) 2017-04-26 2020-07-14 Cavion Inc Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
JP2022540253A (ja) 2019-07-11 2022-09-14 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｔ型カルシウムチャネル調節因子の製剤およびその使用方法
TWI870475B (zh) * 2019-10-02 2025-01-21 美商卡凡恩公司 用於治療神經毒性之方法及材料
CN115776894A (zh) * 2020-04-29 2023-03-10 普拉西斯精密医药公司 T型钙通道调节剂的使用方法
CA3219829A1 (en) * 2021-05-24 2022-12-01 Margaret S. Lee Method of treating essential tremor
AU2024229800A1 (en) * 2023-03-02 2025-09-11 Praxis Precision Medicines, Inc. Methods of treating essential tremor
KR20250165616A (ko) * 2023-03-02 2025-11-26 프락시스 프리시젼 메디신즈, 인크. 고함량 단일 투여 단위 제형 및 이의 사용 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017070680A1 (en) 2015-10-22 2017-04-27 Cavion Llc Methods for treating angelman syndrome and related disorders
JP2018520112A (ja) 2015-05-26 2018-07-26 オディディ，イサ 制御持続放出プレガバリン
JP2018533208A (ja) 2015-10-01 2018-11-08 シリコン ストーリッジ テクノロージー インコーポレイテッドＳｉｌｉｃｏｎ Ｓｔｏｒａｇｅ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 統合された高ｋ金属ゲートを有する不揮発性分割ゲートメモリセル及びそれを作製する方法
JP2019500353A (ja) 2015-12-30 2019-01-10 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100389752C (zh) * 1978-04-21 2008-05-28 莱博法姆公司 控释组合物
DK171349B1 (da) 1986-11-14 1996-09-16 Hoffmann La Roche Tetrahydronaphthalenderivater, fremgangsmåde til fremstilling deraf, lægemidler indeholdende forbindelserne samt anvendelse af forbindelserne til fremstilling af lægemidler
AU2436792A (en) 1991-08-16 1993-03-16 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
CA2749312A1 (en) 1996-02-14 1997-08-21 Novartis Ag Sugar-modified gapped oligonucleotides
WO2001062740A1 (en) 2000-02-25 2001-08-30 South Alabama Medical Science Foundation Mibefradil analogues and their use
CA2443550A1 (en) 2001-04-06 2002-10-24 The Research Foundation Of The City University Of New York Diagnosis and treatment of neural disease and injury using microvoltammetry
CA2469685C (en) 2002-01-17 2013-03-12 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
WO2004003500A1 (en) 2002-07-01 2004-01-08 University Of Manitoba Measuring strain in a structure (bridge) with a (temperature compensated) electromagnetic resonator (microwave cavity)
US20060003985A1 (en) 2002-10-17 2006-01-05 Renger John J Enhancement of sleep with t-type calcium channel antagonists
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
JP2006520799A (ja) * 2003-03-21 2006-09-14 ダイノジェン ファーマシューティカルズ， インコーポレイテッド 平滑筋調節因子およびα２δサブユニットカルシウムチャネル調節因子を用いた、下部尿路障害を処置するための方法
WO2005007124A2 (en) 2003-07-23 2005-01-27 Bristol-Myers Squibb Company Substituted dihydropyrimidine inhibitors of calcium channel function
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
KR100610731B1 (ko) 2004-02-24 2006-08-09 한국과학기술연구원 Ｔ-형 칼슘 채널 차단제로서 유용한 ３,４-디히드로퀴나졸린유도체 및 그의 제조 방법
US7504431B2 (en) 2004-04-16 2009-03-17 Bristol-Myers Squibb Company Sulfonyl amide inhibitors of calcium channel function
WO2006023881A2 (en) 2004-08-20 2006-03-02 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
ATE552233T1 (de) 2004-08-20 2012-04-15 Univ Virginia Patent Found T-typ-calciumkanalinhibitoren
AU2006223469A1 (en) 2005-03-09 2006-09-21 Merck Sharp & Dohme Corp. Quinazolinone T-type calcium channel antagonists
AU2006262101A1 (en) 2005-06-23 2007-01-04 Merck & Co., Inc. 3-fluoro-piperidine T-type calcium channel antagonists
AU2006263564A1 (en) 2005-06-29 2007-01-04 Merck Sharp & Dohme Corp. 4-fluoro-piperidine T-type calcium channel antagonists
WO2007007852A1 (ja) 2005-07-14 2007-01-18 Teijin Chemicals Ltd. 発泡樹脂シートおよび液晶表示装置
KR100654328B1 (ko) 2005-08-26 2006-12-08 한국과학기술연구원 피페라지닐알킬피라졸계 ｔ-타입 칼슘 채널 억제 화합물 및이의 제조방법
JP2009521471A (ja) 2005-12-22 2009-06-04 アイカジェン， インコーポレイテッド カルシウムチャネルアンタゴニスト
PL2010493T3 (pl) 2006-04-12 2016-08-31 Merck Sharp & Dohme Pirydyloamidy jako antagoniści kanałów wapniowych typu t
KR100743255B1 (ko) 2006-05-04 2007-07-27 한국과학기술연구원 Ｔ-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체
KR100749843B1 (ko) 2006-07-13 2007-08-21 한국과학기술연구원 Ｔ-타입 칼슘 채널에 억제 활성을 지닌 신규2,4-디옥소-퀴나졸린 유도체 및 이의 제조방법
KR100969686B1 (ko) 2006-08-07 2010-07-14 한국과학기술연구원 신규한 티아졸계 화합물 및 이를 함유하는 ｔ-형 칼슘 채널저해제
JP2010503676A (ja) 2006-09-15 2010-02-04 シェーリング コーポレイション 疼痛、糖尿病および脂質代謝の障害の治療
AR062789A1 (es) 2006-09-15 2008-12-03 Schering Corp Derivados de azetidina y azetidona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del dolor y de trastornos del metabolismo de los lipidos.
US7884080B2 (en) 2006-09-15 2011-02-08 Schering Plough Corporation Azetidinone derivatives and methods of use thereof
EP2061791A1 (en) 2006-09-15 2009-05-27 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabilism
WO2008033465A1 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
WO2008050200A1 (en) 2006-10-24 2008-05-02 Pfizer Products Inc. Oxadiazole compounds as calcium channel antagonists
US20080227823A1 (en) 2007-03-12 2008-09-18 Hassan Pajouhesh Amide derivatives as calcium channel blockers
US8586619B2 (en) 2007-03-12 2013-11-19 Vm Therapeutics Llc Agents of calcium ion channel modulators
WO2008117148A1 (en) 2007-03-23 2008-10-02 Pfizer Products Inc. Substituted oxadiazole analogs as calcium channel antagonists
WO2008138126A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
KR100863239B1 (ko) 2007-05-23 2008-10-15 한국과학기술연구원 신규한 2-이미노-1,3-티아졸린계 화합물 및 이를 함유하는ｔ-형 칼슘 채널 저해제
CA2692783A1 (en) 2007-07-10 2009-01-15 Merck Sharp & Dohme Corp. Quinazolinone t-type calcium channel antagonists
KR101079459B1 (ko) 2007-09-14 2011-11-03 이화여자대학교 산학협력단 신규한 화합물, 이의 제조방법 및 이를 포함하는 통증억제용 조성물
JP5524071B2 (ja) 2007-10-24 2014-06-18 メルク・シャープ・アンド・ドーム・コーポレーション 複素環フェニルアミドｔ型カルシウムチャネルアンタゴニスト
JP2011500807A (ja) 2007-10-24 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション ピラジニルアミドｔ型カルシウムチャネルアンタゴニスト
AU2008317352A1 (en) 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Heterocycle amide T-type calcium channel antagonists
WO2009056934A1 (en) 2007-10-31 2009-05-07 Pfizer Products Inc. 1,4-dihydronaphthyridine derivatives
KR100917037B1 (ko) 2007-11-01 2009-09-10 한국과학기술연구원 피라졸릴카르복스아미도알킬피페라진 유도체 및 이의제조방법
CA2722706A1 (en) 2008-04-28 2009-11-05 Zalicus Pharmaceuticals Ltd. Di-t-butylphenyl piperazines as calcium channel blockers
ES2764480T3 (es) 2008-04-29 2020-06-03 Impact Coatings Ab Composiciones de combinación para tratar la enfermedad de Alzheimer y trastornos relacionados con zonisamida y acamprosato
US20090298834A1 (en) 2008-06-02 2009-12-03 Hassan Pajouhesh 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers
US8377968B2 (en) 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
KR101014887B1 (ko) 2008-06-26 2011-02-15 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 이미다졸릴알킬카르보닐유도체 및 그의 제조방법
KR20100005476A (ko) 2008-07-07 2010-01-15 한국과학기술연구원 Ｔ-형 칼슘 채널에 활성을 지닌 신규 아이소인돌리논유도체 및 이의 제조방법
US20100137403A1 (en) 2008-07-10 2010-06-03 Scott Malstrom Method for enhancing cognition or inhibiting cognitive decline
KR101052620B1 (ko) 2008-08-28 2011-07-29 한국과학기술연구원 신규 페닐아세테이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 ｔ-형 칼슘 이온 채널의 활성에 의해 유발되는 질환의 예방 또는 치료용 조성물
KR101052065B1 (ko) 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
TW201028421A (en) 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
CN106177963A (zh) 2009-06-05 2016-12-07 陶制药有限责任公司 用于治疗癌症或癌前病症的交错方法
BR112012003179A2 (pt) 2009-08-12 2016-03-01 Carlos Alberto Barcelo Rojas sistema bio-eletrônico
US20130036482A1 (en) 2010-01-29 2013-02-07 National University Corporation Okayama University Method for assessment of potential for development of dravet syndrome and use thereof
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
WO2012032415A2 (en) * 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
WO2012094615A2 (en) 2011-01-07 2012-07-12 Zenyaku Kogyo Kabushikikaisha Use of cav3.1 selective t-type calcium channel antagonists
MX2014013599A (es) 2012-05-08 2015-05-11 Zafgen Inc Tratamiento de la obesidad hipotalamica con inhibidores de metap2.
CN105189775A (zh) 2013-01-10 2015-12-23 陶制药有限责任公司 用于治疗癌症的t-型钙通道抑制剂
US10292989B2 (en) 2014-03-28 2019-05-21 University Of Virginia Patent Foundation General anesthetics that are not neurotoxic
KR101679262B1 (ko) 2015-06-08 2016-11-24 한국과학기술연구원 4-이소프로필크로만-3-올 화합물
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
SG11201909963YA (en) 2017-04-26 2019-11-28 Cavion Inc Methods for treating dravet syndrome
MX2019012818A (es) 2017-04-26 2020-07-14 Cavion Inc Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
GB2571978A (en) 2018-03-15 2019-09-18 Andre Fisahn Uses, compositions and methods
WO2020072773A1 (en) 2018-10-03 2020-04-09 Cavion, Inc. Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
JP2022540253A (ja) * 2019-07-11 2022-09-14 プラクシス プレシジョン メディシンズ， インコーポレイテッド Ｔ型カルシウムチャネル調節因子の製剤およびその使用方法
TWI870475B (zh) 2019-10-02 2025-01-21 美商卡凡恩公司 用於治療神經毒性之方法及材料

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018520112A (ja) 2015-05-26 2018-07-26 オディディ，イサ 制御持続放出プレガバリン
JP2018533208A (ja) 2015-10-01 2018-11-08 シリコン ストーリッジ テクノロージー インコーポレイテッドＳｉｌｉｃｏｎ Ｓｔｏｒａｇｅ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． 統合された高ｋ金属ゲートを有する不揮発性分割ゲートメモリセル及びそれを作製する方法
WO2017070680A1 (en) 2015-10-22 2017-04-27 Cavion Llc Methods for treating angelman syndrome and related disorders
JP2019500353A (ja) 2015-12-30 2019-01-10 アダマス ファーマシューティカルズ， インコーポレイテッド 発作−関連障害の処置のための方法および組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neurotherapeutics，2018年07月09日，Vol.15，pp.819-835，https://doi.org/10.1007/s13311-018-0641-4

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024102139A (ja) * 2018-10-03 2024-07-30 カビオン・インコーポレイテッド （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置

Also Published As

Publication number Publication date
BR112021006398A2 (pt) 2021-07-06
CA3115235A1 (en) 2020-04-09
IL282006B2 (en) 2023-08-01
IL300798B1 (en) 2025-05-01
US12383539B2 (en) 2025-08-12
KR20210087459A (ko) 2021-07-12
EP3860571A1 (en) 2021-08-11
TW202027728A (zh) 2020-08-01
WO2020072773A1 (en) 2020-04-09
CN113164393A (zh) 2021-07-23
US20250312323A1 (en) 2025-10-09
AU2019355021A1 (en) 2021-05-06
MX2025002145A (es) 2025-04-02
US11311522B1 (en) 2022-04-26
IL282006A (en) 2021-05-31
MX2021003706A (es) 2021-11-04
US20220016095A1 (en) 2022-01-20
EP3860571A4 (en) 2022-06-29
IL282006B1 (en) 2023-04-01
JP2024102139A (ja) 2024-07-30
AU2019355021B2 (en) 2024-09-12
TWI879741B (zh) 2025-04-11
JP2022504182A (ja) 2022-01-13
IL300798B2 (en) 2025-09-01
AU2024278171A1 (en) 2025-01-02
WO2020072773A9 (en) 2020-07-16
IL300798A (en) 2023-04-01

Similar Documents

Publication Publication Date Title
JP7480131B2 (ja) （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置
CN102274517B (zh) 治疗帕金森病的方法
JP6853791B2 (ja) パーキンソン病及び関連する障害の治療における使用のための組成物
CN109715144A (zh) 使用双胍类治疗发育障碍的方法
US9561249B2 (en) Pharmaceutical formulations of nitrite and uses thereof
US12503485B2 (en) Human aminosterol ENT-03 compounds, related compositions comprising the same, and methods of using the same
US20190298740A1 (en) Methods and compositions for treating hallucinations and conditions related to the same
US20200129528A1 (en) Methods for treating blood pressure conditions using aminosterol compositions
US20200038420A1 (en) Aminosterol compositions and methods of using the same for treating depression
RU2780318C1 (ru) Лечение эссенциального тремора с помощью (r)-2-(4-изопропилфенил)-n-(1-(5-(2,2,2-трифторэтокси)пиридин-2-ил)этил)ацетамида
HK40057141A (en) Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
CA2753754A1 (en) Methods for treating schizophrenia
US20200038415A1 (en) Aminosterol compositions and methods of using the same for treating erectile dysfunction
US20200038416A1 (en) Methods of treating cardiac conduction defects using aminosterol compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221003

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221003

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240424

R150 Certificate of patent or registration of utility model

Ref document number: 7480131

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150